Macrocyclics
Paul Jurek has extensive experience in the chemical and pharmaceutical industries, currently serving as the Chief Executive Officer of Macrocyclics since June 2004. In addition to this role, Paul Jurek has held positions as Director of Custom Product Development and Quality Manager at Macrocyclics. Prior experience includes a managerial position at Pharmaceutical Systems, Inc. from 2002 to 2004 and a role as a Research Scientist at Superior Graphite from 2000 to 2002. Paul Jurek earned a Ph.D. in Chemistry from Texas A&M University and a B.A. in Chemistry from the University of Jamestown.
This person is not in any teams
This person is not in any offices
Macrocyclics
Macrocyclics, Inc., a manufacturer of customized chelating agents, is dedicated to leading-edge development of new chelation chemistry platforms critical for advancement of diagnostic and therapeutic medicine. We provide a broad library of catalog products designed to meet the needs of our basic and applied research customers as well as custom cGMP products and services to accelerate early stage clinical development programs. We also offer expert consulting services related to fundamental chelation chemistry and bioconjugation. Macrocyclics has a cutting-edge research and development strategy geared toward meeting the emerging needs of the medical community with both commercial and academic collaborations in mind. Our molecular imaging platform technology is adaptable to a broad range of radionuclides such as copper 64, gallium 68 and zirconium 89 for positron emission tomography (PET) and gadolinium and other lanthanide ions for optical and magnetic resonance imaging (MRI). Our products include an extensive line of bifunctional ligands designed specifically for bio-targeting in combination with monoclonal antibodies and peptide fragments. Since 1996, Macrocyclics has been the most trusted name in metal-ligand chelating technologies.